Skip to main content
. Author manuscript; available in PMC: 2013 Jul 29.
Published in final edited form as: Ann Neurol. 2012 Dec;72(6):902–911. doi: 10.1002/ana.23689

TABLE 3.

Clinical Signs and Demographic Features in NMDAR Antibody-Positive versus Antibody-Negative HSE Patients

Sign/Feature NMDAR Antibodies
Probability
Positive Negative

Days between first clinical
signs and admission
6.3 ± 2.8 3.8 ± 2.2 p < 0.05, Mann–Whitney U test

Neuropsychiatric/
neuropsychological symptomsa
3/8 (38%) 5/17 (29%) NS, chi-square = 0.09,
p = 0.76, chi-square test

Epileptic seizures 2/8 (25%) 2/17 (18%) NS, chi-square = 0.49,
p = 0.48, chi-square test

Gender M 6/27 (25%),
F 7/17 (41%)
M 21/27 (75%),
F 10/17 (59%)
NS, chi-square = 1.80,
p = 0.18, chi-square test

Age, yr 53.0 ± 14.2 52.6 ± 17.5 NS, p = 0.84, Mann–Whitney U test
a

For example, confusion, amnestic deficits, behavioral changes.

F = female; HSE = herpes simplex encephalitis; M = male; NMDAR = N-methyl-d-aspartate receptor; NS = not significant.